Mississippi is currently home to 395 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Jackson, Tupelo, Hattiesburg and Flowood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
NCT04331769
Recruiting
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Jackson Heart Clinic, Jackson, Mississippi
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
Register for Updates
Type O Whole Blood and Assessment of Age During Prehospital Resuscitation Trial
NCT04684719
Recruiting
Open label, multi-center, pre-hospital randomized trial utilizing 10 level-1 trauma centers designed to determine the efficacy and safety of low titer whole blood resuscitation as compared to standard of care resuscitation in patients at risk of hemorrhagic shock and to appropriately characterize the hemostatic competency of whole blood relative to its age.
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
03/22/2024
Locations: University of Mississippi Medical Center (UMMC), Jackson, Mississippi
Conditions: Hemorrhagic Shock, Traumatic Injury
Register for Updates
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709
Recruiting
A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or who refuse Cisplantin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. The goal of the study is to explore the triplet combination of Durvalumab, Tremelimumab and Enfortumab Vedotin in terms of efficacy a... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
03/21/2024
Locations: Research Site, Jackson, Mississippi
Conditions: Muscle Invasive Bladder Cancer
Register for Updates
Pediatric Obesity Weight Evaluation Registry (POWER) Study
NCT02121132
Recruiting
The main objective of this study is to establish a national pediatric obesity registry known as POWER (Pediatric Obesity Weight Evaluation Registry). This registry will contain clinical data from individual comprehensive pediatric weight management programs around the United States for overweight and obese youth.
Gender:
All
Ages:
18 years and below
Trial Updated:
03/21/2024
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Overweight, Obesity
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
Management of the PDA Trial
NCT03456336
Recruiting
Estimate the risks and benefits of active treatment versus expectant management of a symptomatic patent ductus arteriosus (sPDA) in premature infants.
Gender:
All
Ages:
Between 48 hours and 21 days
Trial Updated:
03/20/2024
Locations: University of Mississippi Medical Center - Children's of Mississippi, Jackson, Mississippi
Conditions: Infant, Premature, Patent Ductus Arteriosus, Infant, Newborn, Diseases, Patent Ductus Arteriosus After Premature Birth
Register for Updates
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
NCT05862272
Recruiting
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
03/14/2024
Locations: Jackson, Jackson, Mississippi
Conditions: Uterine Fibroids, Endometriosis
Register for Updates
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
NCT03250247
Recruiting
The purpose of this study is to determine if the use of image-guided, endovascular therapy (EVT) is an effective strategy with which to reduce Post Thrombotic Syndrome (PTS) disease severity and improve quality of life in patients with established disabling iliac-obstructive post thrombotic syndrome (DIO-PTS).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Deep Vein Thrombosis, Venous Stasis, Venous Insufficiency, Venous Leg Ulcer, Venous Reflux, Post Thrombotic Syndrome
Register for Updates
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
03/11/2024
Locations: Research Site, Gulfport, Mississippi
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19
NCT05817045
Recruiting
This is a randomized, double-blind, sham controlled, stratified, pivotal efficacy and safety study of the EmitBio RD-X19 treatment device in Individuals 40 Years of age and older with Mild COVID-19 in the at-home setting.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/11/2024
Locations: 318 - Olive Branch Family Medical Center, Olive Branch, Mississippi
Conditions: COVID-19
Register for Updates
Speed of Robotic Leg Movements and Orthostatic Hypotension in Subacute SCI
NCT04029974
Recruiting
This study seeks to evaluate whether the speed (cadence) of lower extremity robotic movement has an impact on orthostatic hypotension and upright tolerance when training with the ErigoPro robotic tilt-stepper. It is hypothesized more frequent short-lasting leg movements (faster cadence) reduces the occurrence/severity of orthostatic hypotension better than less frequent longer-lasting leg movements (slower cadence).
Gender:
All
Ages:
Between 16 years and 70 years
Trial Updated:
03/11/2024
Locations: Methodist Rehabilitation Center, Jackson, Mississippi
Conditions: Spinal Cord Injuries, Orthostatic Hypotension
Register for Updates
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
NCT03887715
Recruiting
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Precise Research Centers, Flowood, Mississippi
Conditions: Treatment Resistant Depression
Register for Updates